1. Home
  2. STTK vs NKLR Comparison

STTK vs NKLR Comparison

Compare STTK & NKLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.95

Market Cap

459.4M

Sector

Health Care

ML Signal

HOLD

NKLR

Terra Innovatum Global N.V. Ordinary shares

N/A

Current Price

$4.89

Market Cap

500.6M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
NKLR
Founded
2016
2018
Country
United States
Italy
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
459.4M
500.6M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
STTK
NKLR
Price
$6.95
$4.89
Analyst Decision
Buy
Strong Buy
Analyst Count
6
3
Target Price
$7.60
$15.00
AVG Volume (30 Days)
502.9K
406.9K
Earning Date
04-30-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
53.02
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$3.73
52 Week High
$7.68
$12.43

Technical Indicators

Market Signals
Indicator
STTK
NKLR
Relative Strength Index (RSI) 65.29 56.65
Support Level $5.75 $3.91
Resistance Level N/A $5.25
Average True Range (ATR) 0.47 0.33
MACD 0.03 0.02
Stochastic Oscillator 61.66 64.59

Price Performance

Historical Comparison
STTK
NKLR

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About NKLR Terra Innovatum Global N.V. Ordinary shares

Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.

Share on Social Networks: